AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 170 filers reported holding AGIOS PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 1.15 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $99,334,125 | -12.6% | 4,013,500 | 0.0% | 1.60% | -1.3% |
| Q2 2023 | $113,662,320 | +23.3% | 4,013,500 | 0.0% | 1.62% | +21.2% |
| Q1 2023 | $92,190,095 | -19.1% | 4,013,500 | -1.1% | 1.34% | -11.5% |
| Q4 2022 | $113,914,719 | -0.8% | 4,056,792 | -0.0% | 1.51% | -8.2% |
| Q3 2022 | $114,783,000 | +27.4% | 4,058,792 | -0.1% | 1.65% | +29.4% |
| Q2 2022 | $90,072,000 | -25.1% | 4,062,792 | -1.6% | 1.27% | -8.8% |
| Q1 2022 | $120,204,000 | -15.9% | 4,129,292 | -5.1% | 1.40% | -5.3% |
| Q4 2021 | $142,961,000 | -28.7% | 4,349,292 | +0.2% | 1.47% | -27.5% |
| Q3 2021 | $200,383,000 | -16.5% | 4,341,992 | -0.3% | 2.03% | -13.2% |
| Q2 2021 | $239,893,000 | +2.4% | 4,352,992 | -4.1% | 2.34% | -5.5% |
| Q1 2021 | $234,295,000 | +28.7% | 4,537,092 | +8.0% | 2.48% | +18.9% |
| Q4 2020 | $182,029,000 | +25.3% | 4,201,002 | +1.2% | 2.08% | +3.9% |
| Q3 2020 | $145,286,000 | -32.5% | 4,151,002 | +3.2% | 2.01% | -34.1% |
| Q2 2020 | $215,181,000 | +55.3% | 4,023,573 | +3.0% | 3.04% | +13.3% |
| Q1 2020 | $138,565,000 | -26.1% | 3,905,444 | -0.5% | 2.69% | -9.6% |
| Q4 2019 | $187,417,000 | +62.0% | 3,924,954 | +9.9% | 2.97% | +38.1% |
| Q3 2019 | $115,718,000 | -25.8% | 3,571,554 | +14.2% | 2.15% | -19.2% |
| Q2 2019 | $156,031,000 | +10084.8% | 3,128,134 | +15650.1% | 2.66% | +2646.4% |
| Q3 2018 | $1,532,000 | -36.9% | 19,861 | -31.1% | 0.10% | -53.1% |
| Q2 2018 | $2,427,000 | -26.4% | 28,811 | -28.5% | 0.21% | -36.7% |
| Q1 2018 | $3,296,000 | +41.0% | 40,300 | -1.5% | 0.33% | +34.0% |
| Q4 2017 | $2,338,000 | -22.2% | 40,900 | -9.1% | 0.24% | -22.3% |
| Q3 2017 | $3,004,000 | +29.8% | 45,000 | 0.0% | 0.31% | +14.6% |
| Q2 2017 | $2,315,000 | -11.9% | 45,000 | 0.0% | 0.27% | -21.7% |
| Q1 2017 | $2,628,000 | +39.9% | 45,000 | 0.0% | 0.35% | -9.1% |
| Q4 2016 | $1,878,000 | -21.0% | 45,000 | 0.0% | 0.38% | -10.3% |
| Q3 2016 | $2,377,000 | +57.6% | 45,000 | +25.0% | 0.43% | +51.1% |
| Q2 2016 | $1,508,000 | -31.2% | 36,000 | -33.3% | 0.28% | -28.6% |
| Q1 2016 | $2,192,000 | – | 54,000 | – | 0.40% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Flagship Ventures 2007 General Partner LLC | 1,930,369 | $118,428,000 | 83.56% |
| Third Rock Ventures, LLC | 3,070,090 | $188,350,000 | 21.97% |
| Opaleye Management Inc. | 113,500 | $6,963,225,000 | 5.43% |
| BB BIOTECH AG | 1,890,521 | $115,983,000 | 4.72% |
| Eventide Asset Management | 431,600 | $26,479,000 | 3.70% |
| Atika Capital Management LLC | 54,000 | $3,313,000 | 2.55% |
| Cormorant Asset Management, LP | 100,000 | $6,135,000 | 1.26% |
| BRIDGER MANAGEMENT, LLC | 220,099 | $13,503,000 | 0.92% |
| Ghost Tree Capital, LLC | 20,000 | $1,227,000 | 0.67% |
| HAMILTON LANE ADVISORS LLC | 27,544 | $1,690,000 | 0.55% |